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CASE PRESENTATION
A 48-year-old African-American man with chronic human
immunodeficiency virus (HIV) infection since 1987 was
referred to our center for renal transplant evaluation.
HIV-associated nephropathy had been diagnosed 8 years
earlier by renal biopsy. Hemodialysis had been initiated 3
years earlier. Past medical history was significant for
hypertension and hyperlipidemia. Before transplantation,
total cholesterol was 178mg per 100ml, low-density
lipoprotein was 40mg per 100ml, and high-density
lipoprotein was 67mg per 100ml without lipid-lowering
therapy. The patient reported no history of earlier
opportunistic infection (OI), malignancy, or co-infection
with hepatitis B virus (HBV) or hepatitis C virus (HCV). He
had been treated with highly active antiretroviral therapy
(HAART) since 1990. After numerous treatment failures,
virologic suppression was finally achieved with a
combination of lamivudine, abacavir, efavirenz, and
lopinavir/ritonavir.
CLINICAL FOLLOW-UP
Deceased-donor renal transplantation was performed without
surgical complication. Peri-transplant induction immuno-
suppressive therapy with antibody preparations was deferred.
Maintenance immunosuppression was instituted with cyclo-
sporine at target serum trough levels of 200 ng/ml, myco-
phenolate mofetil 1 g twice daily, and steroid taper. Target
trough cyclosporine levels were not achieved until cyclos-
porine dosing was reduced to every other day. Creatinine
level at the time of discharge was 1.1mg per 100ml.
In the initial weeks after transplant, his lipid panel was
abnormal: total cholesterol 389mg per 100ml, triglycerides
380mg per 100ml, and low-density lipoprotein 217mg per
100ml. Pravastatin therapy was initiated at 10mg per day
and increased to 20mg over the next 2 months. Fenofibrate
54mg daily was added. Following this intervention, creatine
phosphokinase levels increased to 246U/l without significant
improvement in low-density lipoprotein or total cholesterol.
Pravastatin and fenofibrate therapy were maintained, and
ezetimibe 10mg daily was added at that time. Despite 15
months of therapy, his lipid panel remained abnormal, with
total cholesterol 287mg per 100ml, triglycerides 326mg per
100ml, and low-density lipoprotein 143mg per 100ml.
One year after transplantation, serum creatinine had
increased to 1.7mg per 100ml, without proteinuria. Renal
biopsy showed evidence of significant chronic allograft nephro-
pathy. Calcineurin-inhibitor (CNI)-related nephroxicity was
suspected, and cyclosporine was discontinued in favor of
sirolimus. Prednisone and mycophenolate mofetil were con-
tinued. Therapeutic sirolimus levels of 5–10mg per 100ml were
not achieved until dosing was reduced to 1mg per week.
Lipid abnormalities persisted, however, in the setting of
sirolimus and lopinavir/ritonavir, despite aggressive ongoing
therapy with pravastatin, fenofibrate, and ezetimibe. At this
time, lopinavir/ritonavir was discontinued in favor of atazana-
vir/ritonavir. Fluvastatin was initiated in lieu of pravastatin.
Five years after transplantation, the patient has stable
allograft function (serum creatinine 1.1mg per 100ml).
Immunosuppressive agents include sirolimus, mycophenolate
mofetil, and prednisone. Human immunodeficiency virus
(HIV) has remained stable with continued virologic suppres-
sion, stable CD4 cell counts (4600), and no interim
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development of opportunistic infections (OIs). Lipid ab-
normalities have improved somewhat but persist. Current
medications for hyperlipidemia include ezetmibe, fenofi-
brate, fluvastatin, and colesevelam. The most recent lipid
profile showed: total cholesterol 313mg per 100ml, trigly-
cerides 140mg per 100ml, low-density lipoprotein 177mg
per 100ml, and high-density lipoprotein 108mg per 100ml.
Creatine phosphokinase remains elevated at 544U/l. HIV
medications include lamviudine, abacavir, ritonavir, efavir-
enz, and atazanavir.
DISCUSSION
HIV in renal transplantation
Human immunodeficiency virus-infected dialysis patients in
the 1980s had a very dismal prognosis, and the utility of
offering renal replacement therapy was debated.1 USRDS
data showed an increase in the prevalence of patients with
HIV on hemodialysis from 0.3 to 1.5% from 1985 to 2000,
with a median survival time of only 10 months.2 During this
time period, the mortality ratio of hemodialysis patients with
HIV compared with those without HIV was 2.46 versus 0.63,2
with an improvement in 1-year mortality on dialysis from
56% in 1990 to 74% in 1999.3 The advent of highly active
antiretroviral therapy (HAART) in 1996 led to a decrease in
morbidity and mortality in this patient population.4 Despite
an improvement in outcomes, a 1997 survey of 148 US-based
transplant centers showed that the majority of centers would
not offer cadaveric (88%) or living-donor renal transplanta-
tion (91%) to an asymptomatic patient with HIV despite
otherwise excellent candidacy secondary to medical and
ethical considerations.5 Specifically, survey respondents had
concerns regarding the risks of HIV progression and OI, as
well as the controversy surrounding the utilization of a scarce
resource in a subset of patients with presumed increased
morbidity and mortality. Forty-four percent of the centers
surveyed expressed concern that the expected shortened
survival of HIV-infected patients rendered the use of donated
kidneys unjustified.5 However, in light of recently published
data showing promising outcomes in HIV-infected renal
transplant recipients,6–11 these concerns may no longer be
relevant.
Pre-HAART transplant outcomes in HIV-positive recipients
Data regarding transplant outcomes in the pre-HAART era
are limited due to the small number of patients transplanted
with HIV before the availability of HAART, as well as the
small number of studies in this patient population.12–14 The
largest of these studies, a historical cohort analysis of USRDS
data from 1987 to 1997 showed that patient and graft survival
were significantly reduced in HIV-positive recipients at 3 and
5 years (44 vs 61% 5-year graft survival and 71 vs 78% 5-year
patient survival).12
Post-HAART era
Between 1997 and 2001, a multicenter pilot study was
conducted investigating outcomes in HIV-infected patients
who underwent renal transplantation. Inclusion criteria
included no earlier history of OIs, CD4 count greater than
200/ml, and HIV RNA less than 50 copies/ml. A total of
26 patients received renal allografts. Two deaths occurred,
and two patients developed OIs. The 1-year graft survival,
however, was comparable to other UNOS controls of renal
allograft recipients. In this landmark study, the authors
concluded that these patients should not be excluded from
transplantation.6 A 2003 study of 10 HIV-positive renal
transplant patients showed 100% renal allograft survival at a
mean follow-up of 480 days and a biopsy-proven rejection
rate of almost 50%.7 Subsequent studies evaluating renal
transplantation in HIV-positive patients also showed good
outcomes in selected patients with well-controlled disease
and no co-morbidities.4 None of these patients had
detectable viral loads or histories of OIs. Graft survival rates
in HIVand non-HIV recipients based on UNOS data between
1997 and 2004 were 76.1 vs 65.1%, and patient survival in
these two groups were 91.3 versus 87.3%.8 Another 2005
study prospectively followed 40 dialysis patients between
2001 and 2004 undergoing renal transplantation with a
cyclosporine, sirolimus, and steroid-based immunosuppres-
sion regimen. One-year and 2-year patient survival rates were
85 and 82% with 1- and 2-year graft survival of 75 and 71%.9
More recently, a multicenter study of 1- and 3-year outcomes
in HIV-positive kidney transplant recipients was published,
showing a patient and graft survival similar to the general
transplant population. Despite frequent rejection (52% at 1
year and 73% at 3 years) and a 50% incidence of delayed graft
function, the 3-year kidney allograft loss rate was similar to
that seen among the general transplant population.10
Twenty transplant centers in the United States are offering
HIV-positive patients access to renal transplantation through
an NIH sponsored trial, the Cooperative Clinical Trials in
Adult Transplantation. Selected inclusion and exclusion
criteria are given in Table 1. Patients must otherwise meet
standard criteria for renal transplantation, and enrollment
criteria include well-controlled HIV infection (CD4 count
4200/ml and HIV-1 RNA o50 copies/ml). Patients must be
on a stable antiretroviral regimen for at least 3 months
preceding transplant evaluation. Patients with persistently
undetectable viral loads or long-term non-progressors are
also eligible. Exclusion criteria include solid tumors that have
not been adequately treated and inability to comply with
treatment. Hepatitis C virus-infected patients must undergo
a thorough evaluation that includes quantitative RNA viral
load, genotype, and liver biopsy. Patients without cirrhosis
should be evaluated for therapy with pegylated interferon
and ribavirin before transplantation, as hepatitis C virus can
progress more rapidly in the setting of post-transplant
immunosuppression, and interferon is relatively contra-
indicated following renal transplantation.15 Hepatitis B virus
can be managed and controlled by using a HAART regimen
that includes one or two nucleoside and/or nucleotide reverse
transcriptase inhibitors with activity against both HIV and
hepatitis B virus (for example, lamivudine, emtricitabine, or
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tenofovir). Management of hepatitis B post-transplantation
also includes scheduled administration of hepatitis B
immune globulin.
Post-transplant antibody induction therapy is generally
avoided in this subset of patients due to an increased risk of
serious bacterial infections.16 Following transplantation,
immunosuppressive medications include a calcineurin in-
hibitor (cyclosporine or tacrolimus) and mycophenolate
mofetil with or without steroids based on the institutional
protocol. Rejection episodes must be confirmed by renal
transplant biopsy before treatment.
Prophylactic medications include trimethoprim-sulfa-
methoxazole (one SS or DS tablet daily) for Pneumocystis
and Toxoplasmosis prophylaxis. Alternatively, dapsone with
pyrimethamine and leucovorin, or atovaquone can be used.
When CD4 is o75/ml, azithromycin 1200mg/weekly or
clarithromycin 500mg b.i.d. is also initiated for prophylaxis
against Mycobacterium avium complex infections. Rifabutin
can also be used, but at half the normal dose.15
Post-transplant management issues in the HIV-infected renal
transplant recipient
Immunosuppressants exert an immunomodulatory role in
HIV infection and have been found to have some beneficial
effects. Cyclosporine is thought to have a suppressive effect
on viral replication by inhibiting interleukin-2-dependent
T-cell proliferation.17 In addition, CNIs block nuclear import
of HIV RNA into activated CD4 T cells by inhibiting the
binding of cylophilin to the HIV p24 protein.18 Mycophe-
nolic acid may also synergistically increase the antiviral effect
of abacavir and didanosine, whereas decreased effect may be
seen with the thymidine analogs, stavudine and zidovudine.19
Thus, potentially contradictory effects or toxicity may be
observed.
The clinician must be aware of important drug interac-
tions between antiretroviral agents and immunosuppressants.
These are summarized in Table 2 above. The CNIs, sirolimus,
and protease inhibitors (PIs) are both substrates and
inhibitors of the cytochrome P450 metabolizing enzyme
CYP3A4, resulting in increased systemic blood levels of
CYP3A4 substrates. Accordingly, the maintenance dosing of
CNIs and sirolimus need to be dramatically decreased to
prevent toxicity. On the other hand, non-nucleoside reverse
transcriptase inhibitors (NNRTI) are inducers and can cause
decreased systemic blood levels of CYP3A4 substrate.
Consequently, CNI dosing may need to be increased. Our
patient was receiving both a PI and a NNRTI, resulting in
very complex pharmacokinetics. As a result, the initiation of
Table 1 | Selected inclusion and exclusion criteria for CCTAT15
Inclusion criteria Exclusion criteria
Documented human immunodeficiency virus (HIV) infection (by
enzyme-linked immunosorbent assay with western blot confirmation
or documented history of detectable HIV-1 RNA)
Any history of progressive multifocal leukoencephalopathy (PML),
chronic intestinal cryptosporidiosis of 41 month duration, or
lymphoma (Burkitt’s, immunoblastic, or brain)
Meet standard listing criteria for placement on transplant waiting list History of any neoplasm except: cutaneous Kaposi’s sarcoma,
in situ anogenital carcinoma, adequately treated basal or squamous
cell carcinoma of the skin, solid tumors (except primary CNS lymphoma)
treated with curative therapy and disease-free for more than 5 years.
History of renal cell carcinoma requires 2 years disease-free survival.
CD4+ T-cell count 4200/ml at any time in the 16 weeks before
transplant
Pregnancy
HIV-1 RNA o50 copies/ml by Amplicor Monitor Ultrasensitive
PCR assay or o75 copies/ml by Versant assay for 3 months
Substance use per local site policy
On stable ARV regimen for at least 3 months before entry or
able to maintain a persistently undetectable HIV-1 RNA level
(o50 copies/ml) without the use of ARVs
Inability or unwillingness to comply with the immunosuppression
protocol, ARV therapy, and/or HCV therapy/monitoring, if indicated
Karnofsky performance status X70 Use of interleukin-2 or granulocyte or macrophage-colony-stimulating
factor in the previous 6 months
Not suffering from significant wasting (body mass index
418.5 kg/m2 and not more than 5% weight loss in preceding
3 months)
Cirrhosis on liver biopsy in hepatitis C virus co-infected patients unless
listed for combined liver–kidney transplant
Table 2 | Selected drug interactions between antiretrovirals and immunosuppressive agents18,19
Antiretroviral(s)
Immunosuppressive
agent(s) Interaction Intervention
Protease inhibitor Calcineurin inhibitors Increased levels of calcineurin inhibitors Decrease dose and frequency of calcineurin inhibitors
Protease inhibitor Sirolimus Increased levels of sirolimus Decrease dose and frequency of calcineurin inhibitors
Abacavir, didanosine,
tenofovir
Mycophenolate
mofetil
Possible increased intracellular levels of
abacavir, didanosine, tenofovir
No dose adjustments needed
Efavirenz Calcineurin inhibitors Possible decreased levels of calcineurin
inhibitors
Careful monitoring of calcineurin inhibitors,
with dose adjustments as needed
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both cyclosporine and later sirolimus was complicated by the
need to reduce dosing before achieving target levels and
avoiding toxicity. In general, pharmacokinetic studies suggest
that patients using PIs will require both a reduction of dose
and an increase in dosing interval of the CNI or sirolimus,
whereas patients receiving efavirenz (NNRTI) may require
higher doses of cyclosporine.18,19
Dyslipidemia and increased hepatic triglyceride synthesis
linked to PI use remained problematic in our patient.
Fifty percent of patients on PI therapy develop dyslipidemia
within 2 years. In transplant patients, this problem may be
compounded by the effect of immunosuppressive agents,
particularly sirolimus, cyclosporine, and steroids. Adverse
events including myalgias and liver function abnormalities
have been reported with statin therapy, particularly lovasta-
tin. PIs and NRTIs are both metabolized by the CYP3A4
system, and multiple cases of statin-induced rhabdomyolysis
have been reported in patients on PI therapy, particularly
ritonavir. Simvastatin and lovastatin should be avoided with
PIs, but fluvastatin is considered safe. Care should be taken
when these drugs are used with macrolide antibiotics, as
statin levels may become elevated, precipitating rhabdomyo-
lysis.20 Pravastatin is not metabolized by the CYP3A4 system
and may be a safe option.
Conclusions
Renal transplantation in the era of HIV has been challenging
for transplant nephrologists and infectious disease experts
alike. Exclusion for transplantation on the basis of HIV
infection may soon be a relic of the past. Preliminary data
suggest comparable patient and graft survival rates when
HIV-positive patients are carefully selected. With the wide-
spread use of HAART, patients are living longer and
developing complications related to their co-morbid condi-
tions rather than HIV. Logistical issues that arise in the care
of HIV-positive transplant patients include careful monitor-
ing of calcineurin inhibitor dosing and levels particularly
with PIs and calcineurin inhibitors. HIV-positive patients
and transplant recipients are at risk for developing OIs as
well as malignancies, and a close eye must be kept on the
delicate balance between under- and over-immunosuppres-
sion. Despite its challenges, transplantation in the era of HIV
has been rewarding and preliminary data very encouraging.
Unanswered questions such as the long-term impact of
immunosuppression on HIV reservoirs and CD4 cells
remain, but ongoing multicenter studies may help to
elucidate this in the future.
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